Ask AI
Treatment of HER2-Negative EBC

CE / CME

Expert Review of Treatment for HER2-Negative Early Breast Cancer

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: August 31, 2023

Expiration: August 30, 2024

Activity

Progress
1
Course Completed

Introduction

In this module, Kevin Kalinsky, MD, MS, presents recent clinical data on the treatment of HER2-negative early breast cancer (EBC). He discusses current guideline-recommended biomarker testing, then breaks down the latest strategies for evaluation and treatment of hormone receptor (HR)–positive/HER2-negative EBC, with or without BRCA mutations. Dr. Kalinsky then reviews advances in treatment of early-stage triple-negative breast cancer (TNBC) and mentions ongoing trials evaluating adjuvant and neoadjuvant treatment with immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs).

Please note that the key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with breast cancer do you provide care for in a typical month?

Which of the following assays has an available online tool known as RSClin that incorporates clinical and pathologic features to help individualize risk in node-negative HR-positive/HER2-negative EBC?

Assuming all of the following are available, which would you recommend as next step adjuvant therapy?

What treatment would you recommend?